Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT

NCT04110964 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Limb Ischemia

Interventions

DRUG: AAV-hTERT

Sponsor

Libella Gene Therapeutics